Mucormycosis is a rare but severe opportunistic infection, whose incidence has substantially increased since the coronavirus disease 2019 (COVID‐19) pandemic. It predominantly affects immunocompromised patients, individuals with diabetes, and those receiving corticosteroids. Standard treatment involves extensive debridement of affected tissue combined with prolonged antifungal therapy. We present a case of an immunocompetent patient with no identifiable risk factors who developed maxillary mucormycosis associated with COVID‐19 illness. The condition responded favorably to minimal debridement and antifungal treatment. This case raises questions about the need for extensive debridement in immunocompetent patients without underlying risk factors.
Thepenier et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: